Fixed ratio combination of basal insulin and GLP-1 receptor agonist
Insulin glargine with lixisenatide injection
IGLARLIXI_SC
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.16 (-1.64 to -0.68) | 0.75 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.09 (-1.55 to -0.60) | 0.71 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin glargine | MD -0.50 (-1.47 to 0.49) | 0.87 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 0.10 (-0.57 to 0.70) | 0.71 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -0.12 (-1.14 to 0.92) | 0.46 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.13 (-1.48 to 1.66) | 0.16 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.79 (-1.30 to 2.84) | 0.40 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin glargine | MD -1.09 (-5.85 to 3.71) | 0.42 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 2.10 (-0.23 to 4.94) | 0.63 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -4.19 (-8.98 to 1.10) | 0.63 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 10.55 (2.71 to 24.87) | 0.65 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 10.95 (4.20 to 23.48) | 0.86 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin glargine | OR 2.44 (0.75 to 7.04) | 0.89 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.25 (0.03 to 1.32) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.82 (1.96 to 7.38) | 0.32 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.25 (0.37 to 4.45) | 0.59 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.87 (0.92 to 7.88) | 0.22 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.80 (0.59 to 1.09) | 0.68 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.83 (0.43 to 1.58) | 0.68 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.61 (1.73 to 4.05) | 0.40 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.54 (1.37 to 4.69) | 0.42 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.06 (0.73 to 1.53) | 0.62 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.85 (0.28 to 2.50) | 0.62 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.65 (0.03 to 22.92) | 0.58 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.62 (0.04 to 9.68) | 0.46 |
Trials
- S002992887 randomized · 26 weeks
- IDEALINSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi2021 · 91 randomized · 24 weeks
- Lixilan-O-APA Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)2019 · 878 randomized · 24 weeks
- Lixilan-L-CNA Randomized, 30-week, Active-controlled, Open-label, 2 Treatment-arm, Parallel Group, Multicenter Study Comparing Efficacy and Safety of iGlarLixi to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled on Basal Insulin With or Without Oral Antidiabetic Drug(s)2019 · 426 randomized · 30 weeks
- LIXILAN JP-O1A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period2016 · 321 randomized · 52 weeks
- LIXILAN JP-LA Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs2016 · 513 randomized · 26 weeks
- LIXILAN JP-O2A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine on Top of OADs in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)2016 · 521 randomized · 26 weeks
- LixiLan-LA Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)2014 · 736 randomized · 30 weeks
- LixiLan-OA Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)2014 · 1,170 randomized · 30 weeks
- NCT01476475A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients2011 · 323 randomized · 24 weeks